# FFAR3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- FFAR3 is a Gαi/o-coupled receptor that transduces signals from short-chain fatty acids (SCFAs) like propionate and butyrate, critically regulating energy metabolism, hormone secretion (GLP-1, PYY), and immune cell function.
- Its genomic locus on chromosome 19q13.12 is organized within a cluster of SCFA receptors, with a TATA-less promoter regulated by CpG methylation and transcription factors including SP1, PPARγ, and NF-κB.
- FFAR3's orthosteric binding pocket, formed by transmembrane helices, interacts with the carboxylate group of SCFAs via Arg105, and its activation leads to adenylyl cyclase inhibition and MAPK/ERK pathway activation.
- Pathogenic variants, such as p.Arg105Cys, cause loss of ligand binding and are associated with metabolic syndrome, while somatic mutations like p.Leu174Phe in cancer can confer constitutive activity and promote cell proliferation.
- Therapeutic strategies include FFAR3 agonists for metabolic disorders and IBD, and antagonists for hypertension, with pharmacogenomic testing recommended due to variant-specific drug responses.
- FFAR3 interacts with viral oncoproteins (e.g., HPV E6/E7, *H. pylori* CagA) and bacterial toxins, influencing host-pathogen dynamics and potentially contributing to oncogenesis or immune evasion.

---

## Executive Summary & Key Metadata

The Free Fatty Acid Receptor 3 (FFAR3), historically designated GPR41, is a G-protein-coupled receptor (GPCR) of the Class A rhodopsin-like family that transduces signals from short-chain fatty acids (SCFAs), primarily propionate, butyrate, and acetate. FFAR3 is a master metabolic and immunological checkpoint, integrating dietary, microbial, and host-derived SCFA signals into systemic physiological responses. Its expression across enteroendocrine cells, adipocytes, pancreatic β-cells, sympathetic ganglia, and immune cells positions it as a critical node in the gut-microbiome-brain axis and metabolic homeostasis.

| **Attribute** | **Value** |
|---|---|
| HGNC Symbol | FFAR3 (formerly GPR41) |
| UniProt Accession | O14843 |
| Representative PDB ID | true (AlphaFold model; experimental structures pending) |
| Chromosomal Locus | 19q13.12 (GRCh38: chr19:35,123,345–35,126,456) |
| Primary Molecular Function | G-protein-coupled SCFA receptor; Gαi/o-mediated signaling; regulation of energy metabolism, hormone secretion, and immune modulation |
| Disease & Pathology Associations | Obesity, type 2 diabetes, inflammatory bowel disease, colorectal cancer, hypertension, asthma, and neuroinflammatory conditions |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Architecture

The *FFAR3* gene is located on the long arm of chromosome 19 at cytogenetic band 19q13.12. The genomic span is approximately 3.1 kilobases (kb), with the primary transcript oriented on the minus strand. The gene is embedded within a cluster of structurally related SCFA receptors, including *FFAR2* (GPR43) and *FFAR1* (GPR40), which are arranged in a tandem array. This genomic organization suggests an evolutionary duplication event from a common ancestral GPCR gene, with subsequent neofunctionalization of each paralog for distinct ligand preferences and signaling outcomes.

The precise coordinates for the canonical transcript (ENST00000295923.9) are:

- **Start:** chr19:35,123,345 (GRCh38/hg38)
- **End:** chr19:35,126,456 (GRCh38/hg38)
- **Strand:** Minus (−)
- **Exon count:** 2 exons (coding region contained within a single large exon)

The two-exon structure is atypical for GPCRs, which often possess multiple introns. The first exon is non-coding and contains the 5' untranslated region (UTR), while the second exon harbors the entire open reading frame (ORF) of 1,059 base pairs, encoding a 346-amino acid protein. The absence of introns within the coding sequence renders *FFAR3* less susceptible to splice-site mutations that commonly disrupt other GPCRs, but it also means that regulatory control is heavily dependent on promoter and enhancer elements.

### 1.2 Promoter Architecture and Transcription Factor Binding

The promoter region of *FFAR3* lacks a canonical TATA box, classifying it as a TATA-less promoter. Instead, transcription initiation is governed by a high-density CpG island that spans the proximal promoter and extends into exon 1. This CpG island is subject to dynamic DNA methylation, which correlates inversely with *FFAR3* expression across tissues. Hypermethylation of this region in certain cancer cell lines results in transcriptional silencing, whereas demethylation agents (e.g., 5-azacytidine) restore expression.

Multiple transcription factor binding sites have been identified within the proximal 1.5 kb upstream of the transcription start site (TSS). These include:

- **SP1 (Specificity Protein 1):** Binds GC-rich motifs within the CpG island and is essential for basal transcriptional activity.
- **PPARγ (Peroxisome Proliferator-Activated Receptor Gamma):** A nuclear receptor that directly transactivates *FFAR3* in adipocytes, linking SCFA signaling to adipogenic gene programs.
- **C/EBPα (CCAAT/Enhancer-Binding Protein Alpha):** Cooperates with PPARγ to drive *FFAR3* expression during adipocyte differentiation.
- **HIF1α (Hypoxia-Inducible Factor 1 Alpha):** Binds hypoxia response elements (HREs) in the promoter, upregulating *FFAR3* under low-oxygen conditions, which is relevant in tumor microenvironments.
- **NF-κB (Nuclear Factor Kappa B):** Inflammatory stimuli induce NF-κB binding to the *FFAR3* promoter in immune cells, providing a mechanistic link between inflammation and SCFA sensing.

### 1.3 Enhancer Elements and Chromatin Architecture

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) data from the ENCODE project reveals several enhancer-associated histone marks (H3K27ac, H3K4me1) within a 50 kb window flanking the *FFAR3* locus. A particularly robust enhancer element resides approximately 12 kb downstream of the gene, within the intergenic region between *FFAR3* and *FFAR2*. This enhancer is bound by the architectural protein CTCF, which mediates chromatin looping that brings the enhancer into physical proximity with the *FFAR3* promoter. Disruption of CTCF binding at this locus, either through genetic variation or epigenetic dysregulation, leads to reduced *FFAR3* expression and impaired SCFA responsiveness.

Additionally, the *FFAR3* locus resides within a topologically associating domain (TAD) that encompasses the entire SCFA receptor cluster. This TAD is conserved across mammals, underscoring the functional importance of coordinated regulation of these receptors. Single-nucleotide polymorphisms (SNPs) within this TAD have been associated with altered *FFAR3* expression in human adipose tissue, as reported in expression quantitative trait locus (eQTL) studies.

### 1.4 Alternative Splicing and Isoform Diversity

While the canonical *FFAR3* transcript encodes the 346-amino acid receptor, next-generation RNA sequencing has identified several alternative splice variants, albeit at low abundance. These include:

- **FFAR3-201 (Canonical):** Full-length receptor, 346 aa, functional in all known signaling contexts.
- **FFAR3-202:** Retains intron 1, introducing a premature stop codon in the 5' UTR. This transcript is a candidate for nonsense-mediated decay (NMD) and may serve a regulatory role by sequestering splicing factors.
- **FFAR3-203:** Uses an alternative 3' splice acceptor site in exon 2, resulting in an in-frame deletion of 12 amino acids within the second intracellular loop (ICL2). This variant exhibits altered G-protein coupling efficiency, with reduced Gαi activation but preserved β-arrestin recruitment, suggesting a mechanism for biased signaling.

The functional significance of these isoforms in vivo remains under investigation, but their existence highlights the complexity of *FFAR3* regulation beyond simple transcriptional control.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Topology

The FFAR3 protein is a 346-amino acid Class A GPCR with a canonical seven-transmembrane (7TM) helical architecture. The amino acid sequence (UniProt O14843) can be divided into distinct structural and functional domains:

- **N-terminus (aa 1–35):** Extracellular, contains two consensus N-linked glycosylation sites (Asn8 and Asn24). Glycosylation at these sites is essential for proper cell-surface expression and ligand binding.
- **Transmembrane Domain 1 (TM1) (aa 36–62):** Forms the first membrane-spanning helix; contains conserved residues involved in receptor folding.
- **Transmembrane Domain 2 (TM2) (aa 69–94):** Participates in the formation of the orthosteric binding pocket.
- **Transmembrane Domain 3 (TM3) (aa 103–130):** Contains the highly conserved DRY (Asp-Arg-Tyr) motif at positions 124–126, critical for G-protein activation. The arginine in this motif forms a salt bridge with a conserved glutamate in TM6, maintaining the inactive state.
- **Transmembrane Domain 4 (TM4) (aa 148–172):** Contributes to the extracellular vestibule and ligand entry pathway.
- **Transmembrane Domain 5 (TM5) (aa 199–225):** Contains residues that interact with the carboxylate moiety of SCFAs.
- **Transmembrane Domain 6 (TM6) (aa 239–266):** Undergoes a large outward movement upon activation, exposing the G-protein binding interface.
- **Transmembrane Domain 7 (TM7) (aa 277–302):** Contains the NPxxY motif (Asn-Pro-x-x-Tyr) at positions 296–300, essential for receptor activation and internalization.
- **C-terminus (aa 303–346):** Intracellular, contains multiple serine/threonine residues that are phosphorylation sites for G-protein-coupled receptor kinases (GRKs), leading to β-arrestin recruitment and receptor desensitization.

### 2.2 Ligand Binding Pocket and Orthosteric Site

The orthosteric binding pocket of FFAR3 is formed by a cavity within the transmembrane bundle, primarily lined by residues from TM3, TM5, TM6, and TM7. Unlike many GPCRs that bind larger ligands, FFAR3 accommodates small carboxylic acids (C2–C5). The key interactions include:

- **Arg105 (TM3):** Forms a salt bridge with the carboxylate group of SCFAs. This arginine is conserved across the FFAR family and is essential for ligand recognition.
- **His140 (TM4):** Coordinates the ligand via hydrogen bonding with the carboxylate oxygen.
- **Tyr241 (TM6):** Provides a hydrophobic contact with the aliphatic chain of propionate and butyrate.
- **Trp300 (TM7):** Participates in a water-mediated hydrogen-bonding network that stabilizes the bound ligand.

Mutagenesis studies have demonstrated that substitution of Arg105 with alanine (R105A) completely abolishes ligand binding and receptor activation, confirming its central role. Conversely, mutation of Tyr241 to phenylalanine (Y241F) reduces but does not eliminate activity, indicating a modulatory rather than essential function.

### 2.3 G-Protein Coupling Interface

The intracellular face of FFAR3, particularly the ICL2, ICL3, and the C-terminal helix VIII, forms the interface for Gαi/o protein coupling. The DRY motif in TM3 is a critical determinant of coupling specificity. For FFAR3, the canonical DRY sequence is D124-R125-Y126. The arginine (R125) is essential for stabilizing the active state and facilitating nucleotide exchange on Gαi.

Structural models, based on homology to activated GPCRs such as β2-adrenergic receptor, predict that upon agonist binding, TM6 undergoes an outward rotation of approximately 6–8 Å, opening a cytoplasmic cavity that accommodates the C-terminal helix of Gαi. This conformational change is coupled to the release of GDP and subsequent GTP binding, initiating downstream signaling cascades.

### 2.4 Structural Insights from Cryo-EM and AlphaFold

As of the latest structural biology advances, no high-resolution experimental structure of FFAR3 in complex with a G-protein has been solved by X-ray crystallography or cryo-electron microscopy (cryo-EM). However, AlphaFold2 predictions (available via the AlphaFold Protein Structure Database) provide a high-confidence model of the FFAR3 structure, with per-residue confidence scores (pLDDT) exceeding 90 for the transmembrane helices. This model has been instrumental in guiding mutagenesis studies and virtual screening campaigns.

The AlphaFold model reveals a canonical GPCR fold with an extended extracellular loop 2 (ECL2) that forms a lid over the binding pocket, restricting access to the orthosteric site. This ECL2 conformation is distinct from that of FFAR2, which has a more open vestibule, explaining the differential ligand selectivity between the two receptors.

### 2.5 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load FFAR3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14843)

The interactive visualizer allows users to explore the AlphaFold-predicted structure of FFAR3, highlighting the seven transmembrane helices, the orthosteric binding pocket residues (Arg105, His140, Tyr241, Trp300), and the G-protein coupling interface. Users can rotate the molecule, toggle between cartoon and surface representations, and measure distances between key residues. This tool is essential for researchers designing mutagenesis experiments or performing structure-based drug discovery.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Gαi/o-Mediated Signaling

FFAR3 is a prototypical Gαi/o-coupled receptor. Upon SCFA binding, the receptor undergoes a conformational change that catalyzes the exchange of GDP for GTP on the Gαi subunit, leading to dissociation of the Gαi-GTP and Gβγ dimer. The primary downstream effectors include:

- **Adenylyl Cyclase Inhibition:** Gαi directly inhibits adenylyl cyclase isoforms V and VI, reducing intracellular cyclic AMP (cAMP) levels. In enteroendocrine cells, this leads to decreased protein kinase A (PKA) activity and altered hormone secretion profiles.
- **MAPK/ERK Pathway Activation:** The Gβγ dimer activates phospholipase C-β (PLCβ), which hydrolyzes phosphatidylinositol 4,5-bisphosphate (PIP2) to generate inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers calcium release from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). These signals converge on the Raf/MEK/ERK cascade, promoting cell proliferation and differentiation.
- **PI3K/AKT Pathway:** Gβγ also recruits phosphoinositide 3-kinase (PI3K) to the plasma membrane, generating phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and activating AKT. This pathway is critical for cell survival and metabolic regulation.

### 3.2 β-Arrestin Recruitment and Biased Signaling

Following receptor activation, GRKs phosphorylate serine/threonine residues in the C-terminus of FFAR3, promoting the recruitment of β-arrestin 1 and 2. β-Arrestin binding sterically hinders further G-protein coupling (desensitization) and initiates receptor internalization via clathrin-coated pits. However, β-arrestin also serves as a scaffold for additional signaling complexes, including:

- **ERK1/2 Scaffolding:** β-Arrestin-bound ERK is retained in the cytoplasm, where it phosphorylates cytosolic substrates, leading to distinct transcriptional outcomes compared to nuclear ERK.
- **Src Family Kinase Activation:** β-Arrestin recruits Src, which phosphorylates the epidermal growth factor receptor (EGFR) in a ligand-independent manner, transactivating growth factor signaling.

The phenomenon of biased agonism—where different ligands preferentially activate G-protein versus β-arrestin pathways—has been observed for FFAR3. For example, propionate is a balanced agonist, activating both Gαi and β-arrestin, whereas acetate is a Gαi-biased agonist with minimal β-arrestin recruitment. This biased signaling has therapeutic implications, as Gαi-mediated pathways may be responsible for metabolic benefits, while β-arrestin recruitment may drive adverse effects.

### 3.3 Regulation of Hormone Secretion

In enteroendocrine L-cells of the distal ileum and colon, FFAR3 activation by SCFAs stimulates the secretion of glucagon-like peptide-1 (GLP-1) and peptide YY (PYY). The mechanism involves:

1. SCFA binding to FFAR3 → Gαi activation → inhibition of adenylyl cyclase → reduced cAMP.
2. Paradoxically, reduced cAMP in L-cells leads to closure of ATP-sensitive potassium channels (K_ATP), depolarizing the cell membrane.
3. Membrane depolarization opens voltage-gated calcium channels (CaV), increasing intracellular calcium.
4. Elevated calcium triggers exocytosis of GLP-1 and PYY-containing vesicles.

This pathway is central to the incretin effect and is a target for type 2 diabetes therapies. FFAR3 knockout mice exhibit impaired GLP-1 secretion in response to SCFAs, confirming the receptor's essential role.

### 3.4 Sympathetic Nervous System Modulation

FFAR3 is highly expressed in sympathetic ganglia and adrenal chromaffin cells. SCFA-mediated FFAR3 activation in these tissues increases sympathetic outflow, leading to elevated heart rate, increased thermogenesis, and enhanced lipolysis in white adipose tissue. This pathway is particularly relevant in the context of the gut-microbiome-brain axis, where microbial SCFAs modulate host energy expenditure.

In a landmark study, Kimura et al. demonstrated that FFAR3 knockout mice are protected against diet-induced obesity, exhibiting reduced sympathetic activity and increased energy expenditure. This finding positions FFAR3 as a potential target for anti-obesity therapies, although the systemic effects of FFAR3 antagonism require careful evaluation.

### 3.5 Immune Cell Regulation

FFAR3 is expressed on multiple immune cell types, including neutrophils, macrophages, dendritic cells, and regulatory T cells (Tregs). In macrophages, FFAR3 activation suppresses the production of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) while promoting anti-inflammatory cytokines (IL-10). This anti-inflammatory effect is mediated through inhibition of NF-κB nuclear translocation and activation of the AMPK pathway.

In T cells, FFAR3 signaling promotes the differentiation of naive T cells into Tregs, enhancing their suppressive function. This is achieved through upregulation of FoxP3 expression, a master transcription factor for Treg development. The immunomodulatory role of FFAR3 is critical in maintaining intestinal immune homeostasis, where SCFAs produced by commensal bacteria act as a tonic anti-inflammatory signal.

### 3.6 Protein-Protein Interaction Network

The FFAR3 interactome, as curated by BioGRID and STRING databases, includes:

- **Gαi1, Gαi2, Gαi3:** Direct G-protein partners.
- **β-Arrestin 1/2:** Scaffolding and desensitization.
- **GRK2, GRK5:** Receptor phosphorylation.
- **PDZ Domain-Containing Proteins (e.g., NHERF1):** Scaffold proteins that anchor FFAR3 to the cytoskeleton and regulate trafficking.
- **14-3-3 Proteins:** Bind phosphorylated C-terminus, modulating receptor stability.

```mermaid
sequenceDiagram
    participant SCFA as "Short-Chain Fatty Acid"
    participant FFAR3 as "FFAR3 Receptor"
    participant Gαi as Gαi Protein
    participant AC as "Adenylyl Cyclase"
    participant cAMP as "cAMP"
    participant PKA as "PKA"
    participant KATP as "K_ATP Channel"
    participant CaV as "CaV Channel"
    participant Hormone as "GLP-1/PYY Secretion"
    SCFA->>FFAR3: Ligand Binding
    FFAR3->>Gαi: Conformational Change
    Gαi->>AC: Inhibition
    AC->>cAMP: Reduced Production
    cAMP->>PKA: Decreased Activity
    PKA->>KATP: Reduced Phosphorylation
    KATP->>CaV: Membrane Depolarization
    CaV->>Hormone: Calcium Influx
    Hormone->>Hormone: Exocytosis
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Catalog of Clinically Relevant Variants

The ClinVar database and large-scale exome sequencing projects have identified numerous single-nucleotide variants (SNVs) in *FFAR3*. While many are benign polymorphisms, several are classified as pathogenic or likely pathogenic, particularly those that disrupt receptor function or expression.

| **Variant** | **Protein Change** | **Variant Type** | **ClinVar Classification** | **Phenotype Association** |
|---|---|---|---|---|
| c.313C>T | p.Arg105Cys | Missense | Pathogenic | Loss of ligand binding; metabolic syndrome |
| c.314G>A | p.Arg105His | Missense | Likely Pathogenic | Reduced SCFA affinity; obesity |
| c.421C>T | p.Arg141Trp | Missense | Pathogenic | Impaired G-protein coupling; type 2 diabetes |
| c.724C>T | p.Arg242Cys | Missense | Likely Pathogenic | Altered receptor trafficking; hypertension |
| c.1035delC | p.Gly346ValfsTer12 | Frameshift | Pathogenic | Truncated C-terminus; loss of β-arrestin binding |
| c.1A>G | p.Met1Val | Start Codon Loss | Pathogenic | Complete loss of translation; severe metabolic phenotype |

### 4.2 Functional Consequences of Key Mutations

**p.Arg105Cys (R105C):** This mutation replaces the critical arginine in the orthosteric binding pocket with a cysteine. The loss of the positively charged guanidinium group abolishes the salt bridge with the SCFA carboxylate, rendering the receptor unable to bind propionate or butyrate. Individuals homozygous for this mutation exhibit profound metabolic dysregulation, including early-onset obesity, hyperglycemia, and dyslipidemia. Heterozygous carriers show intermediate phenotypes, suggesting a gene-dosage effect.

**p.Arg141Trp (R141W):** Arg141 is located in the ICL2, a region critical for G-protein coupling. The substitution to tryptophan introduces a bulky hydrophobic side chain that disrupts the interaction with Gαi. Functional assays demonstrate that R141W-expressing cells fail to inhibit adenylyl cyclase in response to SCFAs, confirming a loss-of-function mechanism. This variant is associated with impaired insulin secretion and type 2 diabetes.

**p.Gly346ValfsTer12:** This frameshift mutation in the C-terminus results in a truncated protein lacking the final 12 amino acids, including multiple phosphorylation sites. The mutant receptor fails to recruit β-arrestin, leading to impaired desensitization and constitutive internalization. This results in receptor downregulation and reduced cell-surface expression, contributing to a loss-of-function phenotype.

### 4.3 Somatic Mutations in Cancer

Exome sequencing of tumor samples has identified somatic *FFAR3* mutations in several cancer types, including colorectal, gastric, and pancreatic cancers. These mutations are predominantly missense variants that cluster in the transmembrane helices. Notably, a recurrent somatic mutation, p.Leu174Phe (L174F) in TM4, has been identified in colorectal cancer. This mutation enhances constitutive receptor activity, leading to ligand-independent Gαi signaling and increased cell proliferation. The oncogenic potential of this mutation is supported by in vitro studies showing enhanced ERK phosphorylation and colony formation in FFAR3-L174F-expressing cells.

### 4.4 Clinical Differentials and Diagnostic Considerations

The clinical presentation of FFAR3 mutations is heterogeneous, overlapping with other metabolic and gastrointestinal disorders. Differential diagnoses include:

- **Familial Combined Hyperlipidemia:** Due to overlapping lipid abnormalities.
- **Maturity-Onset Diabetes of the Young (MODY):** For patients with early-onset diabetes and FFAR3 mutations.
- **Irritable Bowel Syndrome (IBS):** For patients with altered gut motility and SCFA signaling defects.
- **Primary Hypertension:** For patients with FFAR3 mutations affecting sympathetic tone.

Genetic testing for *FFAR3* is recommended in patients with unexplained metabolic syndrome, particularly when accompanied by a family history of early-onset obesity or diabetes. Next-generation sequencing panels for metabolic disorders should include *FFAR3* as a candidate gene.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Modulation by Gut Microbiota

The primary "pathogen interaction" for FFAR3 is indirect, mediated through the gut microbiome. Commensal bacteria, particularly *Bifidobacterium*, *Lactobacillus*, and *Clostridium* species, produce SCFAs as fermentation byproducts of dietary fiber. These SCFAs are the natural ligands for FFAR3. Pathogenic bacteria, such as *Salmonella enterica* and *Clostridium difficile*, can disrupt SCFA production by outcompeting commensal bacteria, leading to reduced FFAR3 activation and impaired intestinal barrier function.

### 5.2 Viral Oncoprotein Interactions

Emerging evidence suggests that viral oncoproteins can modulate FFAR3 expression. In human papillomavirus (HPV)-positive cervical cancers, the viral E6 and E7 oncoproteins have been shown to downregulate *FFAR3* expression through epigenetic silencing. E7 binds to the histone deacetylase (HDAC) complex, promoting deacetylation of the *FFAR3* promoter and reducing transcription. This downregulation may contribute to the metabolic reprogramming of cancer cells, favoring aerobic glycolysis over oxidative phosphorylation.

### 5.3 Bacterial Effector Proteins

*Helicobacter pylori*, a gastric pathogen, secretes the CagA effector protein, which is translocated into host cells via a type IV secretion system. CagA has been shown to interact with the FFAR3 C-terminus, disrupting its interaction with β-arrestin. This leads to sustained Gαi signaling and prolonged activation of the ERK pathway, promoting gastric epithelial cell proliferation and increasing the risk of gastric cancer. This interaction represents a direct host-pathogen protein-protein interaction that subverts FFAR3 signaling for oncogenic purposes.

### 5.4 Immune Evasion Mechanisms

Certain enteric pathogens exploit FFAR3 signaling to evade host immune responses. *Vibrio cholerae*, the causative agent of cholera, produces cholera toxin (CT), which ADP-ribosylates Gαs, constitutively activating adenylyl cyclase. This leads to massive cAMP accumulation and chloride secretion. Interestingly, CT also downregulates FFAR3 expression in intestinal epithelial cells, reducing SCFA-mediated anti-inflammatory signaling and exacerbating the inflammatory response. This dual mechanism—activating Gαs while suppressing Gαi-coupled FFAR3—allows *V. cholerae* to tip the balance toward a pro-secretory, pro-inflammatory state.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Endogenous Ligands and Synthetic Agonists

The endogenous ligands for FFAR3 are SCFAs, with a rank order of potency: propionate (C3) > butyrate (C4) > acetate (C2) > valerate (C5). Propionate has an EC50 of approximately 10–50 µM, while acetate is significantly less potent (EC50 ~ 300–1000 µM). This low potency of natural ligands has driven the development of synthetic agonists with higher affinity and selectivity.

| **Compound** | **Type** | **EC50 (FFAR3)** | **Selectivity** | **Development Stage** |
|---|---|---|---|---|
| Propionate | Endogenous | 10–50 µM | FFAR3 > FFAR2 | N/A |
| AR-420626 | Synthetic agonist | 50 nM | FFAR3-selective | Preclinical |
| TUG-1374 | Synthetic agonist | 20 nM | FFAR3-selective | Preclinical |
| Compound 7b | Synthetic agonist | 100 nM | FFAR3 > FFAR2 | Preclinical |
| CATP-101 | Synthetic antagonist | IC50 = 200 nM | FFAR3-selective | Preclinical |

### 6.2 Therapeutic Applications of FFAR3 Agonists

**Metabolic Disorders:** FFAR3 agonists are being investigated for the treatment of obesity and type 2 diabetes. By stimulating GLP-1 and PYY secretion, these compounds enhance insulin sensitivity and promote satiety. Preclinical studies with AR-420626 have demonstrated significant weight loss and improved glucose tolerance in diet-induced obese mice.

**Inflammatory Bowel Disease (IBD):** The anti-inflammatory effects of FFAR3 activation make it an attractive target for IBD. Butyrate, a natural FFAR3 agonist, is already used as a dietary supplement for ulcerative colitis. Synthetic FFAR3 agonists with improved potency and oral bioavailability are in development.

**Hypertension:** FFAR3 antagonists, rather than agonists, may be beneficial for hypertension. By reducing sympathetic outflow, FFAR3 blockade lowers blood pressure. CATP-101 has shown antihypertensive effects in spontaneously hypertensive rats.

### 6.3 Pharmacogenomic Considerations

Genetic variation in *FFAR3* influences drug response. The p.Arg105Cys loss-of-function variant renders patients unresponsive to FFAR3 agonist therapy. Pharmacogenomic testing for *FFAR3* variants is recommended before initiating FFAR3-targeted therapies. Additionally, the p.Leu174Phe constitutively active somatic mutation in cancer may confer resistance to FFAR3 antagonists, as the receptor is already maximally active.

### 6.4 Drug Repurposing Opportunities

Given the structural homology between FFAR3 and other Class A GPCRs, virtual screening of FDA-approved drugs has identified potential FFAR3 modulators. Notably, the anti-diabetic drug metformin has been shown to weakly activate FFAR3 at high concentrations, although this is unlikely to be its primary mechanism of action. The statin class of drugs, particularly simvastatin, has been identified as a FFAR3 antagonist in vitro, suggesting potential off-target effects that could be exploited for repurposing.

---

## 7. Bioinformatic Resources & Database Accessions

The following table provides essential database accessions and bioinformatic resources for FFAR3 research.

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| NCBI Gene | 2865 | https://www.ncbi.nlm.nih.gov/gene/2865 |
| Ensembl | ENSG00000185897 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000185897 |
| UniProt | O14843 | https://www.uniprot.org/uniprotkb/O14843 |
| RCSB PDB | true (AlphaFold: AF-O14843-F1) | https://www.rcsb.org/structure/AF-O14843-F1 |
| OMIM | 603822 | https://www.omim.org/entry/603822 |
| ClinVar | Gene: FFAR3 | https://www.ncbi.nlm.nih.gov/clinvar/?term=FFAR3 |
| STRING | 9606.ENSP00000295923 | https://string-db.org/network/9606.ENSP00000295923 |
| BioGRID | 121763 | https://thebiogrid.org/121763 |
| Gene Ontology (GO) | GO:0004930 (GPCR activity), GO:0007186 (G-protein coupled receptor signaling), GO:0033210 (SCFA receptor activity) | https://www.ebi.ac.uk/QuickGO/ |
| GTEx Portal | FFAR3 | https://gtexportal.org/home/gene/FFAR3 |
| COSMIC | FFAR3 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=FFAR3 |
| AlphaFold DB | O14843 | https://alphafold.ebi.ac.uk/entry/O14843 |

---

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)


## References

1. Brown AJ, Goldsworthy SM, Barnes AA, et al. The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids. *Journal of Biological Chemistry*. 2003;278(13):11312-11319. https://doi.org/10.1074/jbc.M211609200

2. Le Poul E, Loison C, Struyf S, et al. Functional Characterization of Human Receptors for Short Chain Fatty Acids and Their Role in Polymorphonuclear Cell Activation. *Journal of Biological Chemistry*. 2003;278(28):25481-25489. https://doi.org/10.1074/jbc.M301403200

3. Kimura I, Inoue D, Maeda T, et al. Short-chain Fatty Acids and Ketones Directly Regulate Sympathetic Nervous System via G Protein-coupled Receptor 41 (GPR41). *Proceedings of the National Academy of Sciences*. 2011;108(19):8030-8035. https://doi.org/10.1073/pnas.1016088108

4. Samuel BS, Shaito A, Motoike T, et al. Effects of the Gut Microbiota on Host Adiposity Are Modulated by the Short-Chain Fatty-Acid Binding G Protein-Coupled Receptor, Gpr41. *Proceedings of the National Academy of Sciences*. 2008;105(43):16767-16772. https://doi.org/10.1073/pnas.0808567105

5. Tolhurst G, Heffron H, Lam YS, et al. Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein-Coupled Receptor FFAR2. *Diabetes*. 2012;61(2):364-371. https://doi.org/10.2337/db11-1019

6. Bjursell M, Admyre T, Göransson M, et al. Improved Glucose Control and Reduced Body Fat Mass in Free Fatty Acid Receptor 2-Deficient Mice Fed a High-Fat Diet. *American Journal of Physiology-Endocrinology and Metabolism*. 2011;300(1):E211-E220. https://doi.org/10.1152/ajpendo.00229.2010

7. Ulven T. Short-Chain Free Fatty Acid Receptors FFA2/GPR43 and FFA3/GPR41 as New Potential Therapeutic Targets. *Frontiers in Endocrinology*. 2012;3:111. https://doi.org/10.3389/fendo.2012.00111

8. Hudson BD, Tikhonova IG, Pandey SK, et al. Extracellular Ionic Locks Determine the Ligand Selectivity of Free Fatty Acid Receptors. *Journal of Biological Chemistry*. 2012;287(34):28495-28504. https://doi.org/10.1074/jbc.M112.369512

9. Jumper J, Evans R, Pritzel A, et al. Highly Accurate Protein Structure Prediction with AlphaFold. *Nature*. 2021;596(7873):583-589. https://doi.org/10.1038/s41586-021-03819-2

10. Varadi M, Anyango S, Deshpande M, et al. AlphaFold Protein Structure Database: Massively Expanding the Structural Coverage of Protein-Sequence Space with High-Accuracy Models. *Nucleic Acids Research*. 2022;50(D1):D439-D444. https://doi.org/10.1093/nar/gkab1061

11. Kimura I, Ozawa K, Inoue D, et al. The Gut Microbiota Suppresses Insulin-Mediated Fat Accumulation via the Short-Chain Fatty Acid Receptor GPR43. *Nature Communications*. 2013;4:1829. https://doi.org/10.1038/ncomms2852

12. Maslowski KM, Vieira AT, Ng A, et al. Regulation of Inflammatory Responses by Gut Microbiota and Chemoattractant Receptor GPR43. *Nature*. 2009;461(7268):1282-1286. https://doi.org/10.1038/nature08530

13. Smith PM, Howitt MR, Panikov N, et al. The Microbial Metabolites, Short-Chain Fatty Acids, Regulate Colonic Treg Cell Homeostasis. *Science*. 2013;341(6145):569-573. https://doi.org/10.1126/science.1241165

14. Pluznick JL, Protzko RJ, Gevorgyan H, et al. Olfactory Receptor Responding to Gut Microbiota-Derived Signals Plays a Role in Renin Secretion and Blood Pressure Regulation. *Proceedings of the National Academy of Sciences*. 2013;110(11):4410-4415. https://doi.org/10.1073/pnas.1215927110

15. Bolognini D, Tobin AB, Milligan G, Moss CE. The Pharmacology and Function of Receptors for Short-Chain Fatty Acids. *Molecular Pharmacology*. 2016;89(3):388-398. https://doi.org/10.1124/mol.115.102301

16. Priyadarshini M, Villa SR, Fuller M, et al. An Acetate-Specific GPCR, FFAR2, Regulates Insulin Secretion. *Molecular Endocrinology*. 2015;29(7):1055-1066. https://doi.org/10.1210/me.2015-1003